Gleicher Stephanie, Porter Baylee A, Nath Disharee, Li Guanqun, Khanna Rakesh, Goldberg Hanan, Kortylewski Marcin, Bratslavsky Gennady, Kotula Leszek
Department of Urology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
Cancers (Basel). 2021 May 17;13(10):2426. doi: 10.3390/cancers13102426.
Nearly one third of men will incur biochemical recurrence after treatment for localized prostate cancer. Androgen deprivation therapy (ADT) is the therapeutic mainstay; however, some patients will transition to a castrate resistant state (castrate resistant prostate cancer, CRPC). Subjects with CRPC may develop symptomatic metastatic disease (mCRPC) and incur mortality several years later. Prior to metastatic disease, however, men acquire non-metastatic CRPC (nmCRPC) which lends the unique opportunity for intervention to delay disease progression and symptoms. This review addresses current therapies for nmCRPC, as well as novel therapeutics and pathway strategies targeting men with nmCRPC.
近三分之一的男性在接受局限性前列腺癌治疗后会出现生化复发。雄激素剥夺疗法（ADT）是主要的治疗方法；然而，一些患者会转变为去势抵抗状态（去势抵抗性前列腺癌，CRPC）。患有CRPC的患者可能会发展为有症状的转移性疾病（mCRPC），并在几年后死亡。然而，在发生转移性疾病之前，男性会患上非转移性CRPC（nmCRPC），这为干预以延缓疾病进展和症状提供了独特的机会。本文综述了目前针对nmCRPC的治疗方法，以及针对nmCRPC男性的新型治疗方法和通路策略。
Zotero 插件